Written and maintained by CASRAI Editorial Board
Last updated
Short answer: A morpholino is a synthetic antisense oligomer that binds a complementary RNA sequence and blocks it, rather than cutting it, to reduce a gene’s output in cells or embryos. Its uncharged backbone resists nucleases, but that stability does not prove specificity: a morpholino result is only convincing once it has passed independent controls.
General laboratory information for researchers and lab staff, not medical advice. This page describes concepts and validation logic, not a bench protocol.
Definition and scope
Gene Tools, the company that commercialised the chemistry, describes morpholino oligos as tools “for blocking sites on RNA to obstruct cellular processes”. Each subunit is a methylenemorpholine ring carrying one standard base (A, C, G or T), and the rings are joined by non-ionic phosphorodiamidate linkages that replace the anionic phosphates of DNA and RNA. A 25-base morpholino therefore pairs with a 25-base stretch of RNA (Gene Tools, “A Brief Introduction to Morpholino Antisense”, read 2026-11-08).
Because the backbone is uncharged, the oligo is described as completely stable to nucleases. The same source warns that stocks should be kept at or below 1 mM and that drying and freeze-thaw cycles can cause aggregation that reduces activity.
The technique is best known from developmental biology; for the field it comes from, see what developmental biology is.
How morpholinos are used in practice
Translation blocking versus splice blocking
A morpholino acts by steric blocking. Aimed at the start region of an mRNA, it obstructs the translation initiation complex and the RNA is not degraded. Aimed at a splice junction of pre-mRNA, it changes how the transcript is spliced. It can also be aimed at microRNAs or their targets (Gene Tools introduction; Moulton 2007).
The mechanism decides which assay can show an effect. Since a translation blocker leaves the RNA intact, Gene Tools notes that RT-PCR is not suitable for confirming it; protein-level readouts are needed (see our Western blot kit overview). A splice blocker can be checked by RT-PCR because the transcript itself changes (see PCR for genotyping for the assay family).
Delivery
For cultured cells the manufacturer lists scrape-loading, electroporation, microinjection and the Endo-Porter reagent; in animals, Vivo-Morpholinos are delivered by intravenous or local injection. A fluorescein-labelled standard control is described as a way to confirm delivery, giving diffuse cytosolic fluorescence.
Design
Moulton (2007, Current Protocols in Nucleic Acid Chemistry, doi:10.1002/0471142700.nc0430s27; the author works at Gene Tools) describes 25-base oligos, 40-60% CG content for 37 °C systems, checking the target against sequence databases, and using the lowest effective concentration, because “off-target knockdown by any antisense molecule increases with increasing concentration.”
Controls: what each one does and does not show
The most common error with morpholinos is treating one control as proof of specificity. The table sets the controls described in Moulton (2007) and Stainier et al. (2017, PLoS Genetics 13(10): e1007000, published 2017-10-19) against what each can establish.
| Control | What it can show | What it cannot show | Source |
|---|---|---|---|
| Standard control morpholino | Baseline effect of introducing an oligo; accounts for non-specific developmental delay | That the gene-specific phenotype is specific | Moulton 2007; Stainier 2017 |
| 5-base mispair | Helps define the concentration window where the real morpholino acts specifically | Moulton says negative-control use is “not its intended purpose”; Stainier says it cannot establish specificity | Moulton 2007; Stainier 2017 |
| Invert control (same composition, reversed order) | An additional sequence-matched comparison | Specificity on its own | Moulton 2007 |
| Second non-overlapping morpholino (a different 5′-UTR site, or two splice blockers on one exon) | Whether a different oligo against the same gene gives the same phenotype | Absence of shared off-target effects at high dose | Moulton 2007; Stainier 2017 (ATG plus splice, or combine with CRISPR) |
| mRNA or DNA rescue lacking the morpholino site | Whether restoring the gene reverses the phenotype | Moulton notes it “cannot work for some genes when used in embryos” | Moulton 2007; Stainier 2017 |
| Comparison with a mutant | Whether the morphant matches the mutant phenotype | A morphant that differs from the mutant is treated as not validated for that phenotype | Stainier 2017 |
Moulton also advises against a sense-strand control. Stainier et al. add a dose-response curve, extra caution when high amounts are needed for a phenotype, and no longer recommend the co-injected target-GFP fusion test for ATG morpholinos.
Where it matters for lab decisions
The 2017 zebrafish guidelines state that morpholinos “should be used alongside mutant(s) for the corresponding gene”, and treat effects present in the morphant but absent from the mutant as off-target. For a lab planning a knockdown, the practical consequence of that guidance is to plan for more than one line of evidence, for example two non-overlapping oligos plus a rescue or a mutant comparison, rather than one oligo with a standard control. These guidelines were written for zebrafish; the control logic is set out more generally in Moulton (2007). Funder expectations on rigor are summarised in the NIH rigor and reproducibility policy entry, and the general idea in reproducibility.
Common misunderstandings
- “Nuclease-resistant means specific.” Stability describes the backbone. Specificity has to be shown with controls. Moulton notes a single mismatch in a 25-mer may markedly reduce activity, yet about 14 contiguous matching bases can be enough to be active.
- “The mispair control is my negative control.” The standard control is the negative control; the mispair is for defining the concentration window.
- “Morpholinos degrade the RNA.” They block; a translation blocker leaves the RNA intact, which is why RT-PCR is the wrong confirmation for it.
Frequently asked questions
What is a morpholino?
A synthetic antisense oligomer with morpholine rings and phosphorodiamidate linkages that binds complementary RNA and blocks it sterically.
Does a morpholino cut or degrade RNA?
No. It blocks translation initiation or splice sites; the RNA is not degraded by a translation blocker.
How is a splice-blocking morpholino checked?
The manufacturer states that splice blocking can be checked by RT-PCR, since the transcript changes.
Is a morphant phenotype enough on its own?
Current zebrafish guidance says no: pair it with a mutant, a second oligo or rescue.
Sources
- Gene Tools, “A Brief Introduction to Morpholino Antisense”: gene-tools.com/node/11 (read 2026-11-08; manufacturer).
- Moulton JD. “Using Morpholinos to Control Gene Expression.” Current Protocols in Nucleic Acid Chemistry, 2007: PMC7162184 (read 2026-11-08; author affiliated with Gene Tools).
- Stainier DYR et al. “Guidelines for morpholino use in zebrafish.” PLoS Genetics 13(10): e1007000, 2017: journals.plos.org (read 2026-11-08).
